Quintiles in Greater China
Integrating global expertise and local insight to
improve your probability of success™
Greater
China
Established
in Greater
China since
1997
China:
Unique opportunities and challenges
require unique solutions
According to the data from IMS, in 2014 China became the second largest
biopharmaceutical market in the world. Driven by increasing income levels
and an aging population, increased healthcare spending will translate into
growth potential. Now more than ever, it is critical for biopharma companies
to rely on superior clinical development capabilities in China in order to
navigate this environment and take advantage of the opportunities. Quintiles
has the global expertise and local insight to help you expand your drug
portfolio – and gain market access in China, the Asia Pacific region and
across the globe.
Your partner of choice for drug development
in Greater China
•Positioned in Greater China since 1997, located
in all major cities across the region, including
Hong Kong and Taiwan
•Service offerings across every major
therapeutic area and through every phase
of clinical development
•Quintiles Global Delivery Network (GDN)
Center in Dalian provides data management,
biostatistics and pharmacovigilance solutions in
multiple languages including Chinese, English,
Japanese and Korean
•Kun Tuo, a wholly owned subsidiary of Quintiles,
provides customized local solution to support
both innovative drug and device development
in China
•Established Medical Affairs team provides world
class expertise and resources in Real World
Study, Medical Science Liaison and Nurse
Educator areas
The Quintiles advantage:
World class expertise for superior delivery of
clinical trials
• CRAs receive extensive training in ICH GCP and
Quintiles SOP.
• Projects are covered by a comprehensive risk
assessment plan and quality management plan
developed by experienced project managers.
• Quintiles Quality Management Team supports monitoring
operations to improve quality by proactively identifying,
assessing and prioritizing potential quality risks.
• Experienced QA team helps to support audits, track
quality issues, develop corrective plan and conduct
training to improve quality.
Meet your timelines and improve your probability
of success
In China, Taiwan and Hong Kong, from August 2014 to
August 2015, 86% of studies hit LPLV (Last Patient Last
Visit) on time.
86%
86% of studies
hit LPLV on time
Multinational pharmaceutical companies trust Quintiles
as the first global CRO to provide high quality clinical trial
management services in China. In the past 18 years, we have
established great working relationships with local hospitals,
investigators and regulatory authorities. Combining our local
insight with our global footprint and expertise, Quintiles can
help you bring your drugs to market faster and accelerate
market adoption.
Apply industry-leading expertise to different
therapeutic areas to provide superior delivery
Quintiles has a track record of therapeutic success in China
since 2005, including Phase I, II, III, IIIb, IV and observational
studies across all major therapeutic areas.
>470
studies
81,730
patients
We also have a track record of therapeutic success
in Taiwan since 2000.
185
studies
5,187
patients
An experienced and stable project team offers continuity
and deep expertise.
Our staff in China and Taiwan have a high retention rate over
the past five years.
Local pharmaceutical companies choose Quintiles as
the experienced partner with the proven capabilities and
expertise to power drug development. We can help you
increase your probability of success in drug development,
from early phase trials to commercialization. Our local,
regional and global medical and operations experts can help
you improve trial design, obtain regulatory approval, achieve
delivery and meet timelines so you can get your drug to
market faster.
The Quintiles Asia Pacific
Emerging Biopharma Solution
For local pharmaceutical companies, Quintiles has now
tailored our leading clinical development model to meet the
specific needs and budget of Greater China’s emerging
biopharma companies with our new Quintiles Asia Pacific
Emerging Biopharma Solution. This solution focuses
on your unique objectives – because we understand how
important your study is to your future and what it takes to
help reach your goals. It represents a new approach, tailored
for the world’s most diverse and dynamic healthcare market,
without any trade-offs.
The Quintiles advantage:
Therapeutic expertise
Gain access to global experts in your therapeutic area to
help improve plan and design clinical trials. Quintiles has
14 dedicated therapeutic Centers of Excellence offering
deeper expertise in:
Close relationship with investigators and sites to carry
out patient enrollment and project delivery
• Acute care & pain
• Oncology
• Developed 14 major hospitals into Prime, Partner and
Alliance sites with contractual agreement and dedicated
support from Quintiles Site Service team
• Biosimilars
• Pediatrics
• Cardiac safety
• Psychiatry
• Cardiovascular
• Respiratory/allergy
• Established China Advisory Board 4 years ago to connect
KOL and healthcare experts in China with Quintiles senior
leadership to promote clinical research and patient safety
• Diabetes
• Rheumatology
• Gastroenterology
• Provide ICH-GCP training to selected investigators and
sites through training classes and workshops, with more
than 2,300 investigators and study coordinators trained
since 2012
• Medical devices
• Vaccines/infectious
diseases
• Neurology
Quintiles helped develop
or commercialize 98 of
the Top 100 best-selling
products of 2014.
Phase I units worldwide
In addition to Quintiles-owned units in Overland Park, USA
and London, UK, we have access to Phase I units across Asia
Pacific – Australia, China, Hong Kong, South Korea, Malaysia,
New Zealand, Singapore, Thailand and Taiwan. We also
have access to Phase I units in Czech Republic, Poland and
Hungary in Europe.
Superior benefits for customers
We offer accelerated patient
enrollment throughout the
world, with:
25
>1,200
>36,000
prime
sites
partner sites
partner
investigators
• Tailored operational model aligning our world-class services,
expertise and scale to your locations and budget
• Data access and performance analytics delivered by our
proprietary Quintiles Infosario® technology to help track
progress throughout your study
Awards
• BioPharma Asia Industry Awards Best
CRO in Asia, 2011, 2012, 2014
• Frost & Sullivan Asia Pacific CRO of the Year,
2006, 2010, 2011, 2012, 2014, 2015
• Best CRO in Vaccine Industry Excellence Asia, 2011, 2012
Quintiles has the global expertise and local insight to help
you expand your drug portfolio and gain market access in
China, Asia Pacific and across the globe. Contact us today
to learn more.
Ranked #3 in the healthcare industry on FORTUNE
Magazine’s list of the World’s Most Admired Companies
CRO Leadership Awards, 2014
Best CRO, SCRIP Awards 2013, 2014
Best CRO for the third time in the last four years
at the Vaccine Industry Excellence Awards
• Best Technological Development in Clinical Trials
(Quintiles Infosario®), SCRIP Awards
InformationWeek Elite 100
2013 Informatica Innovation Award
Computerworld Data+ Editor’s Choice Award
Contact us
Toll free: +86 4008810237
Website: www.quintiles.com/china
Email: [email protected]
Copyright © 2015 Quintiles. All rights reserved. 01.0046-1-12.15
• Society for Clinical Research Sites’ Eagle
Award 2013, 2014, 2015